Herceptin is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Herceptin is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameHerceptin
Authorized generictrastuzumab
Regular generictrastuzumab
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Herceptin?
The original
–
–

Brand nameThe maker’s card

Genentech Oncology Co-pay Assistance Program

Savings card from Genentech

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a treatment

The card takes up to $25,000 a year off your co-pay.

Sign up on herceptin.com 

Or call 1-888-249-4918.

In the maker’s words

“With the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $0 per treatment for Herceptin.”

From the maker’s offer on herceptin.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Herceptin itself, from the same company, sold without the brand name, and usually for less. For now Herceptin is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Herceptin is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

Herceptin is a HER2/neu receptor antagonist indicated in adults for:

  • The treatment of HER2-overexpressing breast cancer.
  • The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin.

Source: the FDA label for Herceptin (Genentech, Inc.), May 29, 2026. Full label on DailyMed 

Good to know